Nivolumab + Relatlimab Clinical Trials
6 recruitingDrug
Phase 12Phase 32Phase 22
Showing 1–6 of 6 trials
Recruiting
Phase 2
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
MelanomaAdvanced MelanomaMelanoma Stage IV+1 more
H. Lee Moffitt Cancer Center and Research Institute90 enrolled1 locationNCT06295159
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 3
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Advanced Melanoma
Replimune Inc.400 enrolled73 locationsNCT06264180
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Renal Cell Carcinoma (RCC)
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaClinical Stage I Cutaneous Melanoma AJCC v8+6 more
Carlo Contreras36 enrolled1 locationNCT04697576
Recruiting
Phase 3
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Advanced Melanoma
Immunocore Ltd680 enrolled211 locationsNCT06112314